Oxybate sodium for parkinsonism. 1973

P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006885 Hydroxybutyrates Salts and esters of hydroxybutyric acid. Hydroxybutyric Acid Derivatives,Hydroxybutyric Acids,Acid Derivatives, Hydroxybutyric
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
March 2006, The Annals of pharmacotherapy,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
August 2006, Expert review of neurotherapeutics,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
June 2011, Nature reviews. Rheumatology,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
April 2016, BMJ (Clinical research ed.),
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
December 2012, Prescrire international,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
September 2010, Sleep & breathing = Schlaf & Atmung,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
August 2011, Expert opinion on pharmacotherapy,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
February 2005, Expert opinion on pharmacotherapy,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
June 2002, Pharmacotherapy,
P S Papavasiliou, and G C Cotzias, and I Mena, and M Bell
November 2020, Sleep medicine,
Copied contents to your clipboard!